Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors
Crossref DOI link: https://0-doi-org.brum.beds.ac.uk/10.1186/s12967-016-0852-6
Published Online: 2016-04-19
Published Print: 2016-12
Update policy: https://0-doi-org.brum.beds.ac.uk/10.1007/springer_crossmark_policy
Schreuer, Max
Meersseman, Geert
Van Den Herrewegen, Sari
Jansen, Yanina
Chevolet, Ines
Bott, Ambre
Wilgenhof, Sofie
Seremet, Teofila
Jacobs, Bart
Buyl, Ronald
Maertens, Geert
Neyns, Bart
Funding for this research was provided by:
Vlaamse Liga Tegen Kanker (44501190, 445290)